Back to top
more

Mersana Therapeutics (MRSN)

(Delayed Data from NSDQ)

$6.61 USD

6.61
88,676

-0.09 (-1.34%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $6.56 -0.05 (-0.76%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -17.14% and +33.71%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 9.52% and 62.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of -44.44% and 10.25%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -109.76% and 91.70%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 31.25% and 154.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 14.52% and 2.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 50% and 32.82%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 233.33% and 86.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 143.75% and 76.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -11.11% and 72.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wave Life Sciences (WVE) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Wave Life Sciences (WVE) delivered earnings and revenue surprises of -56.25% and 20.58%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -8.33% and 4.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates

by Zacks Equity Research

Biogen (BIIB) delivered earnings and revenue surprises of 32% and 3.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Seer (SEER) delivered earnings and revenue surprises of -3.23% and 13.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 14.48% and 33.88%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

by Zacks Equity Research

Curis (CRIS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of 20% and 62.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Stoke Therapeutics, Inc. (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a Turnaround

by Zacks Equity Research

The heavy selling pressure might have exhausted for Mersana Therapeutics, Inc. (MRSN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -20.51% and 54.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?